Acquisition by Robert DeLuccia of 19737 shares of Acurx Pharmaceuticals at 3.8 subject to Rule 16b-3
ACXP Stock | USD 1.25 0.10 8.70% |
Slightly above 53% of Acurx Pharmaceuticals' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Acurx Pharmaceuticals LLC suggests that some traders are interested. Acurx Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Acurx Pharmaceuticals LLC. Many technical investors use Acurx Pharmaceuticals LLC stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Acurx |
Filed transaction by Acurx Pharmaceuticals LLC Director, 10 Percent Owner . Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Acurx Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Acurx Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Acurx Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Acurx Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Acurx Pharmaceuticals Fundamental Analysis
We analyze Acurx Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acurx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acurx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Acurx Pharmaceuticals is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Acurx Pharmaceuticals LLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acurx Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Acurx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acurx Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Acurx Pharmaceuticals Related Equities
MNPR | Monopar Therapeutics | 6.43 | ||||
MLYS | Mineralys Therapeutics, | 4.71 | ||||
RZLT | Rezolute | 4.18 | ||||
ADAG | Adagene | 4.05 | ||||
ACRV | Acrivon Therapeutics, | 2.31 | ||||
SILO | Silo Pharma | 2.27 | ||||
ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
PMVP | Pmv Pharmaceuticals | 0.63 | ||||
CADL | Candel Therapeutics | 0.00 | ||||
LUMO | Lumos Pharma | 0.46 | ||||
ANTX | AN2 Therapeutics | 1.44 | ||||
AVTE | Aerovate Therapeutics | 1.49 |
Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.